docetaxel anhydrous has been researched along with Weight Loss in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beckmann, MW; de Gregorio, N; Fasching, PA; Fehm, T; Friedl, TWP; Harbeck, N; Jäger, B; Janni, W; Jückstock, J; Mahner, S; Mohrmann, S; Mutschler, NS; Rack, B; Salmen, J; Schochter, F; Scholz, C; Weissenbacher, T; Widschwendter, P; Ziegler, C; Zwingers, T | 1 |
| Bernadach, M; Biau, J; Dillies, AF; Durando, X; Kwiatkowski, F; Lapeyre, M; Miroir, J; Moreau, J; Pham-Dang, N; Saroul, N | 1 |
| Parlak, C; Selek, U; Topkan, E | 1 |
| Baciuchka, M; Berdah, JF; Beuzeboc, P; Bousquet, G; Dauba, J; Delva, R; Deplanque, G; El Kouri, C; Esterni, B; Eymard, JC; Ferrero, JM; Fizazi, K; Gravis, G; Habibian, M; Hasbini, A; Joly, F; Krakowski, I; Labourey, JL; Laguerre, B; Latorzeff, I; Linassier, C; Machiels, JP; Marino, P; Mourey, L; Oudard, S; Platini, C; Pouessel, D; Priou, F; Ravaud, A; Rolland, F; Soulie, M; Suc, E; Théodore, C; Zanetta, S | 1 |
| Alsina, M; Aranda, E; Cano, MT; Conde, V; Díaz-Rubio, E; Galán, M; García de Paredes, ML; López, C; Manzano, JL; Martínez Galán, J; Massutí, B; Pachón, V; Reboredo, M; Rivera, F; Salcedo, M; Sastre, J; Serrano, R; Valladares-Ayerbes, M; Yuste Izquierdo, AL | 1 |
| Chen, Y; Gao, L; Hong, C; Hong, Y; Jin, Y; Lu, L; Mao, G; Qin, Z; Su, D; Wei, Y; Wu, G; Ye, X; Yuan, G; Zhao, T; Zhou, H; Zhou, Y | 1 |
| Dueck, A; Jatoi, A; Loprinzi, CL; Luyun, RF; Mattar, BI; Nguyen, PL; Nikcevich, DA; Ritter, HL | 1 |
| Buiret, G; Céruse, P; Combe, C; Ecochard, R; Favrel, V; Fayette, J; Martin, L; Pommier, P; Ramade, A; Tartas, S | 1 |
| Coyle, C; Dyker, K; Öksüz, DÇ; Prestwich, RJ; Şen, M | 1 |
| Ge, Y; Jiang, X; Jin, Y; Liu, X; Shu, Y; Van, S; Yang, D; Yu, L | 1 |
| Ford, J; Jatoi, A; Jett, JR; Loprinzi, CL; Novotny, P; Prabhakar, U; Sloan, J | 1 |
| Olszewski, W | 1 |
| Amsrud, T; Chen, V; Forler, PA; Menon, K; Phares, VG; Shih, C; Teicher, BA | 1 |
4 trial(s) available for docetaxel anhydrous and Weight Loss
| Article | Year |
|---|---|
Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Germany; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Weight Gain; Weight Loss | 2018 |
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Docetaxel; Fatigue; Hot Flashes; Humans; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Physician-Patient Relations; Prostatic Neoplasms; Self-Assessment; Sexual Dysfunction, Physiological; Surveys and Questionnaires; Taxoids; Weight Gain; Weight Loss | 2014 |
Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Endpoint Determination; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Weight Loss | 2015 |
A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Docetaxel; Double-Blind Method; Fatigue; Female; Genetic Association Studies; Genotype; Humans; Infliximab; Lung Neoplasms; Male; Polymorphism, Genetic; Quality of Life; Taxoids; Tumor Necrosis Factor-alpha; Weight Loss | 2010 |
9 other study(ies) available for docetaxel anhydrous and Weight Loss
| Article | Year |
|---|---|
[Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: The importance of nutritional status].
Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Enteral Nutrition; Febrile Neutropenia; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infections; Male; Middle Aged; Nutritional Status; Retrospective Studies; Thrombocytopenia; Tumor Burden; Weight Loss | 2019 |
Impact of weight change during the course of concurrent chemoradiation therapy on outcomes in stage IIIB non-small cell lung cancer patients: retrospective analysis of 425 patients.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Weight; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Retrospective Studies; Survival Analysis; Taxoids; Vinblastine; Vinorelbine; Weight Gain; Weight Loss | 2013 |
CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Taxoids; Weight Loss | 2016 |
A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Clinical Protocols; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; France; Head and Neck Neoplasms; Hospitalization; Humans; Male; Middle Aged; Radiodermatitis; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Stomatitis; Taxoids; Weight Loss | 2010 |
Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Enteral Nutrition; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Radiation-Sensitizing Agents; Taxoids; Weight Loss | 2011 |
Synthesis, characterization, and in vivo efficacy evaluation of PGG-docetaxel conjugate for potential cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dipeptides; Docetaxel; Drug Carriers; Hemolysis; Humans; Mice; Mice, Inbred BALB C; Nanoconjugates; Particle Size; Polymers; Rats; Solubility; Taxoids; Weight Loss; Xenograft Model Antitumor Assays | 2012 |
A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients.
Topics: Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Gastrointestinal Agents; Humans; Infliximab; Lung Neoplasms; Male; Pilot Projects; Taxoids; Weight Loss | 2004 |
Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema.
Topics: Anthropometry; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capillary Permeability; Carcinoma; Docetaxel; Double-Blind Method; Edema; Electronics, Medical; Female; Flavonoids; Humans; Leg; Lymphedema; Mastectomy; Optics and Photonics; Ovarian Neoplasms; Paclitaxel; Placebos; Randomized Controlled Trials as Topic; Taxoids; Venous Insufficiency; Weight Loss | 2000 |
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; Humans; Injections, Intraperitoneal; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Weight Loss | 2000 |